Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NexoBrid (anacaulase-bcdb) is a topically administered biological product that enzymatically removes nonviable burn tissue, or eschar, in patients with deep partial and full-thickness thermal burns.
Product Name : NexoBrid
Product Type : Enzyme
Upfront Cash : Inapplicable
September 20, 2023
Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vericel Announces FDA Approval of NexoBrid for the Treatment of Severe Thermal Burns in Adults
Details : NexoBrid (anacaulase-bcdb) is a botanical drug product containing proteolytic enzymes indicated for the removal of eschar in adults with deep partial or full-thickness thermal burns.
Product Name : NexoBrid
Product Type : Enzyme
Upfront Cash : Inapplicable
December 29, 2022
Lead Product(s) : Bromelain
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cultured Epidermal Autograft
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data published in the Journal of Burn Care & Research for Epicel® (cultured epidermal autografts) showed 83% of patients with posterior burns (mean total body surface area of 56%) had successful engraftment of Epicel after one or two applications.
Product Name : Epicel
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 21, 2022
Lead Product(s) : Cultured Epidermal Autograft
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable